Inloggen

Login
 
Wachtwoord vergeten?

Biocartis forum geopend

Volgen
 
Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
3.049 Posts
Pagina: «« 1 ... 134 135 136 137 138 ... 153 »» | Laatste | Omlaag ↓
  1. Flatlander 28 maart 2020 22:11
    www.genomeweb.com/pcr/mobidiag-garner...

    The article reiterates the urgent need for a Fast TAT Sepsis test.

    I read that BCART IR department said they would begin shipping the Septicyte test this summer. Seems like in the midst of a global pandemic where Sepsis is a major contributing factor in mortality that they could have worked with the EU to coordinate a faster launch to market. For half a year ImmunExpress has been stating that EU approval of Septicyte would be received in the 1st quarter 2020. I guess I'm too use to large pharma investments, where they are prepared to launch new drugs immediately on receipt of a drug approval.

    Rarezot if your out there, is this likely to represent a typical launch timeframe or are other factors such as limited availability of reagents playing a role? I understand that COVID 19 testing is sucking up a lot of the reagents from other PCR MDx testing.

    FL


  2. brightlight 30 maart 2020 20:38
    FL
    I am still trying to get my head around the valid observation made by MB that Bcart will be able to charge much higher cartridge prices in the US once full approval is achieved, and more importantly what that would mean to the total avg cartridge selling price. I suppose that, because Bcart already has CE-marking in Europe, they currently are already able to charge full price in Europe (and ROW?). So only in the US there is still the potential for a serious price hike. I am right? So assuming a substantial price hike in the US, how much would the total avg cartridge selling price then end up to be in your opinion? We are currently at an avg price of 103E. Verrelst pointed out (if I understood him correctly) that this current avg price includes a lot of discounts because the old Fisher stock had to sold before expiration date. Probably the real current avg price is more in the region of 110 to 120. What is your take on where the total avg selling price may end up?
    Concerning console prices, much to my surprise, I just discovered Ceph's current console prices are perfectly in line with Bcart's. So I wonder if there is any room for Idylla prices to go up significantly. I was also astonished by Ceph's cartridge prices (link below). Your valuable insights are more than welcome, as always.
    BL
    www.finddx.org/pricing/genexpert/
  3. Flatlander 31 maart 2020 16:11
    BL

    I recall visiting the Fisher website in June 2019 before BCART instituted discounting to move product approaching expiration. I tried to find my notes but must have thrown them out. From memory this is the pricing I recall. I've provided the EAC article reimbursement rates (I posted a few weeks ago) or other rates I could find on-line.

    test Cost pack of 6 single cartridge Reimbursement Estimated Future*
    USD USD USD USD
    MSI $1500 $250 $500^ $350
    EGFR $1200 $200 $324.58 $280
    KRAS $800 $133.33 $193.25 $180
    * - Estimated future pricing assuming diagnostic use authorization
    ^ estimate from fightlynch.org

    I've estimated a 40% increase in the US. This is an initial price increase (generally around 40%) is intended to leave considerable profit margin for the POC practice to drive adoption. I would assume that BCART could further raise prices (maybe toward 60%) as idylla is incorporated into the POC work flow. This all assumes that medicare and the insurers continue to reimburse based on the specific MDx panel and does not institute some type of IVD discount. This is of course specific to the US. Previous posts indicate that reimbursement rates are lower in the EU. I suspect that all of Asia will eventually be supported by a low cost manufacturing line located in China.

    The key is becoming ingrained in the routine workflow at the POC. If there is a significant profit margin, I believe it will really drive adoption.

    Regards
    FL



  4. Rarezot 31 maart 2020 16:25
    quote:

    Flatlander schreef op 27 maart 2020 14:22:


    Rarezot

    What is the time frame for BCART to start producing significant Septicyte cartridges? What are the limitations (reagents, trained personnel, etc.) to trying to expedite production?

    FL


    Hey FL, I'm sorry for the late response. Took a couple of days off.

    If they produce it on the 2nd line, I don't axpect many problems for personnel. I am not sure about the first line, but I don't expect it to change all too much either.
    The beauty of the BCART cartridge is that it will always operate with the same basic parts. Yes there are some parts that aren't used in some cartridges, so they just need their checklist of the parts needed and put them on the production line. Everything is scanned, so it's implausible to take wrong parts (and they are checked by the production line, so maybe they will have some rejects before figuring out they are using wrong parts).

    The biggest time drain is for calibration and maybe teaching the camera checks. That is entirely dependable on what goes into the cartridge and how different it is from the ones produced now. It is impossible to put an accurate time frame on that. If it is only some liquid changes, it can be like a week. If they need new parts that aren't used now 3-6 months... It can be something as stupid as having to use a different kind of plastic to entirely mess up camera checks, weight check, laser welding, ...

    So I'm not too worried about parts or training. Validation takes a run (usually 3 days), then the parts have to be tested (another week).
    I don't know about any other paperwork after that... (and maybe that is reduced in the current circumstances).

    So if the new cartridge isn't too different from what is used now, I would guess about 1 month...
    If there are some significant changes, it won't be ready during the current pandemic.

    We also don't know how long BCART was working on it before the announcement, so let's try and stay positive ;)

    Rarezot
  5. Flatlander 31 maart 2020 16:50
    BL

    "US$ 17,000 (Price ex works & prepaid) US$ 17,500 (Price ex works & prepaid)"

    The GenExpert Consol cost is for a 4 channel unit. the unit cost would be $4,375 for a single channel unit. This is less than the $5500 Fisher showed as the list price last year. The $5500 obviously included some mark up for Fisher as distributor. So I think your correct that the Idylla console is priced similarly (slightly higher) than GenExpert. However, I think that Idylla has more proprietary technology on the front end to liquify a homogenize the tumor sample, so higher list prices are justified. The big difference is the volume of samples inherent in infectious disease vs oncology.

    I would think the console pricing remains stable for a few years until the POC usage is established. When they can get enough practitioner case studies to demonstrate that Idylla can be a profit center for say a Urology practice, they would have leverage to raise prices for new sale of consoles.

    FL
  6. Flatlander 31 maart 2020 17:00
    BL

    One last assumption. Verrelst has in the past indicated that the Asia manufacturing line cost will be a fraction of the Mechelen line costs. The engineering and sourcing has been completed such that it can be easily applied to Asia. Labor costs would also be much lower. That said, I don't think we need to worry about this until 2021.

    FL
  7. Flatlander 31 maart 2020 18:24
    I believe that ImmunExpress will receive FDA approval (probably an Emergency Use) approval for septicyte rapid in the near future. The FDA is moving applications for any testing that can benefit COVID 19 treatment through in record time (a week or two). However, this may not matter much, if the cartridges will not be ready to ship for a couple months.

    FL
  8. brightlight 31 maart 2020 18:53
    quote:

    Flatlander schreef op 31 maart 2020 16:50:


    BL

    "US$ 17,000 (Price ex works & prepaid) US$ 17,500 (Price ex works & prepaid)"

    The GenExpert Consol cost is for a 4 channel unit. the unit cost would be $4,375 for a single channel unit. This is less than the $5500 Fisher showed as the list price last year. The $5500 obviously included some mark up for Fisher as distributor. So I think your correct that the Idylla console is priced similarly (slightly higher) than GenExpert. However, I think that Idylla has more proprietary technology on the front end to liquify a homogenize the tumor sample, so higher list prices are justified. The big difference is the volume of samples inherent in infectious disease vs oncology.

    I would think the console pricing remains stable for a few years until the POC usage is established. When they can get enough practitioner case studies to demonstrate that Idylla can be a profit center for say a Urology practice, they would have leverage to raise prices for new sale of consoles.

    FL

    The GenExpert prices are discount prices for (some) governments/countries. I suppose that is governments/countries with hospitals run by the state. Do you think it would be a good idea for Bcart to address these markets too?

    What do you mean by "The big difference is the volume of samples inherent in infectious disease vs oncology. "?
    BL
  9. brightlight 31 maart 2020 19:12
    quote:

    Flatlander schreef op 31 maart 2020 17:00:


    BL

    One last assumption. Verrelst has in the past indicated that the Asia manufacturing line cost will be a fraction of the Mechelen line costs. The engineering and sourcing has been completed such that it can be easily applied to Asia. Labor costs would also be much lower. That said, I don't think we need to worry about this until 2021.

    FL

    I think the main worry for the moment would be the cash burn. I hope you have a valid point that Bcart will soon (2021?) get considerable milestone payments to offset the cash burn. Even though I considered it to be a real possibility, I find it hard to imagine that Bcart would really have to raise cash on top of the convertible. I agree management must still have a card up their sleeve to avoid such outcome. All things considered, it would make a lot of sense they have.
    BL
  10. brightlight 31 maart 2020 19:29
    quote:

    Flatlander schreef op 31 maart 2020 16:11:


    BL

    I recall visiting the Fisher website in June 2019 before BCART instituted discounting to move product approaching expiration. I tried to find my notes but must have thrown them out. From memory this is the pricing I recall. I've provided the EAC article reimbursement rates (I posted a few weeks ago) or other rates I could find on-line.

    test Cost pack of 6 single cartridge Reimbursement Estimated Future*
    USD USD USD USD
    MSI $1500 $250 $500^ $350
    EGFR $1200 $200 $324.58 $280
    KRAS $800 $133.33 $193.25 $180
    * - Estimated future pricing assuming diagnostic use authorization
    ^ estimate from fightlynch.org

    I've estimated a 40% increase in the US. This is an initial price increase (generally around 40%) is intended to leave considerable profit margin for the POC practice to drive adoption. I would assume that BCART could further raise prices (maybe toward 60%) as idylla is incorporated into the POC work flow. This all assumes that medicare and the insurers continue to reimburse based on the specific MDx panel and does not institute some type of IVD discount. This is of course specific to the US. Previous posts indicate that reimbursement rates are lower in the EU. I suspect that all of Asia will eventually be supported by a low cost manufacturing line located in China.

    The key is becoming ingrained in the routine workflow at the POC. If there is a significant profit margin, I believe it will really drive adoption.

    Regards
    FL

    If your pricing from memory is correct, then the average price in the US for RUO cartridges (roughly around 180$) must already have been higher than CE-marked prices in Europe. This is the only explanation why the global average stood at only 103 Euro, last year. I would have expected the contrary. To get such a low global average Bcart must surely have been giving discounts in Europe too. Bearing this in mind, I find it extremely hard to figure out what the global avg. selling price would be under normal circumstances for fully authorized assays.
    BL
  11. Flatlander 31 maart 2020 22:37
    Rarezot

    "We also don't know how long BCART was working on it before the announcement, so let's try and stay positive ;)"

    The "available by Summer" comment was attributed to Renate.

    Lees meer op: beursig.com/forum/viewtopic.php?f=4&a... voor meer informatiee

    Your timeline is not far off is you consider that they have probably built in some contingency time to deal with shipping and channel disruptions.

    Regards FL
  12. Flatlander 31 maart 2020 22:43
    BL

    Fig 2 of the attached report indicates that the infectious disease is 62% of the Global MDx market compared to only 20% for genomics. Since the cost of infectious disease assays are much lower than oncology, the volume of tests must be much greater to account for the market percentage difference.

    www.eacorp.com/wp-content/uploads/201...

    FL
  13. Flatlander 31 maart 2020 23:19
    quote:

    brightlight schreef op 31 maart 2020 19:29:


    [...]
    If your pricing from memory is correct, then the average price in the US for RUO cartridges (roughly around 180$) must already have been higher than CE-marked prices in Europe. This is the only explanation why the global average stood at only 103 Euro, last year. I would have expected the contrary. To get such a low global average Bcart must surely have been giving discounts in Europe too. Bearing this in mind, I find it extremely hard to figure out what the global avg. selling price would be under normal circumstances for fully authorized assays.
    BL


    If you go back to the conference calls last year, I know Verrelst has stated that prices were higher in the US. An analyst questioned him about the margins when they began to slide when they started heavily discounting in mid 2019. Part of the difference besides currency is that they were paying Fisher as a 3rd party distributor and they had additional shipping costs. The pricing difference between the EU and the US is the main reason BCART anticipated that the US would quickly eclipse the EU in revenue generation (they provided a broad discussion only, since they do not provide specific geographic breakdown).

    With regards to a global ave selling price, it is going to be very hard to estimate with the information we have. From what I can tell, there is push back in the US to further reimbursement rate cuts. You are likely to arrive at an average for the developed world and one for emerging markets. If you can uncover reimbursement rates from governments then you could apply some type of geriatric population weight factor, apply a discount for POC incentive and then average the results. It's an interesting exercise. While China and India have huge populations the production costs have to come way down for them to afford it. Hence the reason for the low cost manufacturing line. That said, NGS may not be as big a competitor in these emerging markets as older more labor intensive sequencing methods. Idylla will have speed and accuracy advantages over these older methods if the labor costs are low, these older methods may be utilized for years.

    FL

  14. brightlight 1 april 2020 08:58
    FL
    Interesting thoughts, as always. Since the pricing of cartridges is the single most influential item for the bottom line, I want to elaborate on that a bit more.
    For 2019 we have an actual avg. global price of 103 Euro per cartridge. This was arrived at, we suspect, with an avg. price per cartridge in the US of approximately 180$, on which a serious discount was applied because of Thermo. So let's say for the sake of argument that the avg. price in the US would have been around 110$ or 100 Euro. This means that to get to a global avg. of 103, the avg price for Europe and ROW must also (!) have been extremely low, also around 100 Euro. So Bcart must have been discounting heavily in Europe and ROW too, I suspect, for one reason or other??? In a study dating back to 2015 (I know it is old) the avg global Bcart assay price was estimated to be around 230 Euro. This avg was then (in 2015) partly based on Bcart management estimates. I would not pin my hopes on that number too much, but assuming 2019 was a year of discounts across the board, and assuming prices in the US can go a lot higher (after full approval), then the global avg. price will have considerable room to go up. As a reminder, 161 Euro was Bcart's global avg assay price in 2016. On the other hand, sales in China may bring the number back down again, as you rightly point out. So, taking all of this into account, we possibly could go back to the 160 area again (maybe 200, let's hope) in the not too distant future. This seems reasonable to me. But there are a lot of ifs. We will have to wait to see what happens.
    BL
  15. verkoop 1 april 2020 12:13
    Cookie Policy

    Resources
    Blog
    Journalists

    Log In
    Sign Up
    Data Privacy
    Send a Release

    [PR Newswire: news distribution, targeting and monitoring]

    News
    Products
    Contact

    Search

    News in Focus
    Business & Money
    Science & Tech
    Lifestyle & Health
    Policy & Public Interest
    People & Culture

    Send a Release

    News

    News in Focus
    Business & Money
    Science & Tech
    Lifestyle & Health
    Policy & Public Interest
    People & Culture

    Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte® RAPID

    SeptiCyte® RAPID can swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis

    Commercialization of SeptiCyte® to triage COVID-19 patients will be the focus of Biocartis partnership in Europe
    (PRNewsfoto/Immunexpress, Inc.)

    News provided by
    Immunexpress, Inc.

    Mar 26, 2020, 02:00 ET

    Share this article

    SEATTLE and BRISBANE, Australia, March 26, 2020 /PRNewswire/ -- Immunexpress, Inc. a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced it has received CE Marking of SeptiCyte® RAPID for its host response technology. SeptiCyte® RAPID combines SeptiCyte® technology with the Biocartis Idylla™ platform, providing actionable results in about one hour to guide the physician to optimize patient management decisions.

    The CE Marking of SeptiCyte® RAPID is a significant accomplishment for Immunexpress, enabling the company to market and sell the near-patient sample-to-answer test in European Union (EU) member countries and those harmonized with the EU IVD Directive (98/79/EC). Immunexpress plans to immediately initiate commercial operations in Europe, and announced a long-term commercialization partnership with Biocartis NV, an industry leader in the molecular diagnostic space. Biocartis currently has over 1,300 Idylla™ instruments installed throughout the world.

    "Achieving the CE IVD registration and entering commercialization of Immunexpress' leading host response SeptiCyte technology represents a new and exciting phase for our company," said Rolland Carlson, Ph.D., Chief Executive Officer of Immunexpress. "We believe Biocartis, with its well established and growing customer base, will be highly effective in delivering to the European community a new and novel sepsis diagnostic tool, designed to enhance the certainty of early and rapid sepsis diagnosis, to improve clinical outcomes and to lower healthcare costs."

    The ongoing COVID-19 pandemic underscores the unmet need for technologies that efficiently discriminate patients with mild infection from those that may develop serious complications related to sepsis, especially when critical medical resources are in short supply. In a recent study of the risk factors associated with COVID-19 mortality, sepsis was the most frequently observed complication1. The early diagnosis of bacterial and viral sepsis with SeptiCyte® RAPID, including the immediate and overwhelming global need to triage COVID-19 patients with worsening prognoses, will ensure rapid initiation of sepsis management protocols increasing the potential to save lives.

    Dr. Carlson continued, "Together with Biocartis, Immunexpress is committed to mitigating the constraints on hospitals that are affected by the COVID-19 pandemic. We are urgently working towards improving patient outcomes by swiftly triaging COVID-19 patients to receive the most appropriate treatment. Accurate diagnostic testing of sepsis is more important now than ever to enable physicians to make rapid clinical decisions in resource-constrained ICUs."

    About SeptiCyte® RAPID

    SeptiCyte® RAPID is a gene expression assay using reverse transcription polymerase chain reaction (PCR) to quantify the relative expression levels of host response genes isolated from whole blood collected in the PAXgene® Blood RNA Tube. SeptiCyte® RAPID is used in conjunction with clinical assessments, vital signs and laboratory findings as an aid to differentiate infection-positive (sepsis) from infection-negative systemic inflammation in patients suspected of sepsis. SeptiCyte® RAPID generates a score (SeptiScore™) that falls within one of three discrete Interpretation Bands based on the increasing likelihood of infection-positive systemic inflammation. SeptiCyte® RAPID is intended for in-vitro diagnostic use and is used on the Biocartis Idylla™ System.

    About Biocartis
    Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs in oncology. This represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_.

    About Immunexpress
    Immunexpress is a molecular diagnostic company, founded in Australian and based out of Seattle, Washington, USA, committed to improving outcomes for patients suspected of sepsis. Immunexpress' SeptiCyte® technology can assess a patient's immune response by quantifying and analyzing gene expression signatures from whole blood, providing actionable results in about an hour to guide the physician in optimizing patient management decisions. SeptiCyte® RAPID combines SeptiCyte® technology with the Biocartis' Idylla™ platform*, empowering clinicians to swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis. This powerful combination of technologies enhances certainty for early sepsis diagnosis, to improve clinical outcomes and lower healthcare costs. For more information visit www.immunexpress.com/.

    Follow Immunexpress on Twitter and LinkedIn.

    *Immunexpress is licensed to use the Idylla™ trademark from Biocartis NV.

  16. DRTVR 1 april 2020 16:05
    quote:

    verkoop schreef op 1 april 2020 12:13:


    Cookie Policy

    Resources
    Blog
    Journalists

    Log In
    Sign Up
    Data Privacy
    Send a Release

    [PR Newswire: news distribution, targeting and monitoring]

    News
    Products
    Contact

    Search

    News in Focus
    Business & Money
    Science & Tech
    Lifestyle & Health
    Policy & Public Interest
    People & Culture

    Send a Release

    News

    News in Focus
    Business & Money
    Science & Tech
    Lifestyle & Health
    Policy & Public Interest
    People & Culture

    Immunexpress Receives CE Mark and Signs European Commercialization Partnership for SeptiCyte® RAPID

    SeptiCyte® RAPID can swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis

    Commercialization of SeptiCyte® to triage COVID-19 patients will be the focus of Biocartis partnership in Europe
    (PRNewsfoto/Immunexpress, Inc.)

    News provided by
    Immunexpress, Inc.

    Mar 26, 2020, 02:00 ET

    Share this article

    SEATTLE and BRISBANE, Australia, March 26, 2020 /PRNewswire/ -- Immunexpress, Inc. a molecular diagnostic company focused on improving outcomes for suspected sepsis patients, today announced it has received CE Marking of SeptiCyte® RAPID for its host response technology. SeptiCyte® RAPID combines SeptiCyte® technology with the Biocartis Idylla™ platform, providing actionable results in about one hour to guide the physician to optimize patient management decisions.

    The CE Marking of SeptiCyte® RAPID is a significant accomplishment for Immunexpress, enabling the company to market and sell the near-patient sample-to-answer test in European Union (EU) member countries and those harmonized with the EU IVD Directive (98/79/EC). Immunexpress plans to immediately initiate commercial operations in Europe, and announced a long-term commercialization partnership with Biocartis NV, an industry leader in the molecular diagnostic space. Biocartis currently has over 1,300 Idylla™ instruments installed throughout the world.

    "Achieving the CE IVD registration and entering commercialization of Immunexpress' leading host response SeptiCyte technology represents a new and exciting phase for our company," said Rolland Carlson, Ph.D., Chief Executive Officer of Immunexpress. "We believe Biocartis, with its well established and growing customer base, will be highly effective in delivering to the European community a new and novel sepsis diagnostic tool, designed to enhance the certainty of early and rapid sepsis diagnosis, to improve clinical outcomes and to lower healthcare costs."

    The ongoing COVID-19 pandemic underscores the unmet need for technologies that efficiently discriminate patients with mild infection from those that may develop serious complications related to sepsis, especially when critical medical resources are in short supply. In a recent study of the risk factors associated with COVID-19 mortality, sepsis was the most frequently observed complication1. The early diagnosis of bacterial and viral sepsis with SeptiCyte® RAPID, including the immediate and overwhelming global need to triage COVID-19 patients with worsening prognoses, will ensure rapid initiation of sepsis management protocols increasing the potential to save lives.

    Dr. Carlson continued, "Together with Biocartis, Immunexpress is committed to mitigating the constraints on hospitals that are affected by the COVID-19 pandemic. We are urgently working towards improving patient outcomes by swiftly triaging COVID-19 patients to receive the most appropriate treatment. Accurate diagnostic testing of sepsis is more important now than ever to enable physicians to make rapid clinical decisions in resource-constrained ICUs."

    About SeptiCyte® RAPID

    SeptiCyte® RAPID is a gene expression assay using reverse transcription polymerase chain reaction (PCR) to quantify the relative expression levels of host response genes isolated from whole blood collected in the PAXgene® Blood RNA Tube. SeptiCyte® RAPID is used in conjunction with clinical assessments, vital signs and laboratory findings as an aid to differentiate infection-positive (sepsis) from infection-negative systemic inflammation in patients suspected of sepsis. SeptiCyte® RAPID generates a score (SeptiScore™) that falls within one of three discrete Interpretation Bands based on the increasing likelihood of infection-positive systemic inflammation. SeptiCyte® RAPID is intended for in-vitro diagnostic use and is used on the Biocartis Idylla™ System.

    About Biocartis
    Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla™ platform is a fully automated sample-to-result, real-time PCR system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis is developing and marketing a continuously expanding test menu addressing key unmet clinical needs in oncology. This represents the fastest growing segment of the MDx market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal and lung cancer. More information: www.biocartis.com. Follow us on Twitter: @Biocartis_.

    About Immunexpress
    Immunexpress is a molecular diagnostic company, founded in Australian and based out of Seattle, Washington, USA, committed to improving outcomes for patients suspected of sepsis. Immunexpress' SeptiCyte® technology can assess a patient's immune response by quantifying and analyzing gene expression signatures from whole blood, providing actionable results in about an hour to guide the physician in optimizing patient management decisions. SeptiCyte® RAPID combines SeptiCyte® technology with the Biocartis' Idylla™ platform*, empowering clinicians to swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients suspected of sepsis. This powerful combination of technologies enhances certainty for early sepsis diagnosis, to improve clinical outcomes and lower healthcare costs. For more information visit www.immunexpress.com/.

    Follow Immunexpress on Twitter and LinkedIn.

    *Immunexpress is licensed to use the Idylla™ trademark from Biocartis NV.




    Mooi nieuws en zeker geen aprilgrap.
  17. Flatlander 1 april 2020 17:20
    BL

    Unfortunately even with near future diagnostic approvals, the end payer in many markets in the near future are governments who are going to be increasingly cash strapped after dealing with COVID 19. I'm confident of BCARTs ability to compete on pricing with NGS methods. NGS generally entails higher equipment costs, greater lab tech time, shipping, cold chain, etc. These factors combined with the much higher failure rates make Idylla assays attractive. So a synergistic relationship is likely to develop on a larger scale. Full genomic mapping via NGS and fast focused analyses on Idylla to identify a specific MDx target.

    The suppression of assay pricing that you discuss is likely a conscious effort of larger testing labs to continue using cheaper PCR sequencing methods (pyro, Sanger etc sequencing). While these older PCR methods are less accurate, require more prep time, reagents, room space etc., there is considerable inertia to change. Governments are looking at high unemployment, so automation that results in the loss of lab tech jobs may get some resistance in the current market climate. Where Idylla is used as a tool that allows technicians to meet an ever increasing work load, it will be welcomed. Ultimately, I think the Big Pharma companies will drive adoption at the POC level. Pharma will probably increasingly pay for some or all of the CDx analysis. they can justify this as a cost of doing business/acquiring the scripts. The high cost of these drugs make it worthwhile for the Pharma to pay some or all of the assay cost.

    I foresee numerous genomic testing firms shuttering in the next year as it becomes increasingly difficult to raise cash in this environment. BCART is in an enviable situation since they have cash to ride out a couple years to hopefully reach the other side of this Covid valley. However, stemming cash burn could be critical going into 2021. If we can trust management, this will happen through the sales inflection point we have long awaited. This inflection point is associated with diagnostic use registrations in several geographies and new product launches, both of which have proven to be elusive.

    Regards
    FL

  18. forum rang 10 voda 2 april 2020 07:23
    PERSBERICHT: Persbericht Biocartis Group NV: Biocartis kondigt publicatie van 2019 jaarverslag aan

    FONDS KOERS VERSCHIL VERSCHIL % BEURS
    Biocartis NV
    3,425 0,00 0,00 % Euronext Brussel

    PERSBERICHT: GEREGLEMENTEERDE INFORMATIE

    2 april 2020, 07:00 CEST


    Biocartis kondigt publicatie van 2019 jaarverslag aan

    Mechelen, België, 2 april 2020 -- Biocartis Group NV (de
    'Vennootschap' of 'Biocartis'), een innovatief bedrijf in de moleculaire
    diagnostiek (Euronext Brussels: BCART), kondigt vandaag de publicatie
    van zijn 2019 jaarverslag aan.

    Het 2019 jaarverslag biedt een overzicht van de cijfers en prestaties
    van Biocartis voor het boekjaar afgesloten op 31 december 2019, en kan
    nu als PDF-bestand worden gedownload van de website van de Vennootschap
    (
    www.globenewswire.com/Tracker?data=4K...
    investors.biocartis.com/nl).

    --- EINDE ---

    Meer informatie:

    Renate Degrave

    Head of Corporate Communications & Investor Relations Biocartis

    e-mail
    www.globenewswire.com/Tracker?data=Sd...
    rdegrave@biocartis.com

    tel +32 15 631 729

    gsm +32 471 53 60 64

    www.globenewswire.com/Tracker?data=i4...
    www.linkedin.com/Biocartis
3.049 Posts
Pagina: «« 1 ... 134 135 136 137 138 ... 153 »» | Laatste |Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Biocartis Meer »

Koers 4,910   Verschil -0,01 (-0,10%)
Laag 4,715   Volume 272.650
Hoog 4,910   Gem. Volume 312.168
29 mei 2020 17:35
label premium

Biocartis herpakt zich

Het laatste advies leest u als IEX Premium-lid

Inloggen Ontdek Premium
 
Quotedata: Amsterdam realtime by Euronext, other realtime by Cboe Europe Ltd.   US stocks: by NYSE & Cboe BZX Exchange, 15min delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by VWD Group Crypto data by Crypto Compare